Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder joined Proactive's Stephen Gunnion with details of company’s latest financial results and future outlook. Barder highlighted that Futura Medical has increased guidance on both profit and revenue for the remainder of the year. Its flagship product, Eroxon, a clinically proven treatment for erectile dysfunction, has now launched in ten countries, with its most recent debut in Mexico.
Barder emphasised the significance of Eroxon entering the US market as the first over-the-counter (OTC) treatment for erectile dysfunction, where competitors like Viagra and Cialis still require a prescription. He also mentioned the company’s strategy for sustainable growth and the development of a strong product pipeline, which includes future launches in other regions.
He concluded by sharing Futura Medical’s milestone achievement of generating its first profit, with revenue increasing by over 300% to £7 million. With a robust R&D team and expansion efforts underway, Barder expressed optimism about continued growth and building a viable consumer healthcare company.